phenprocoumon (liquamar) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Phenprocoumon is the dominant anticoagulant in clinical use in several continental European countries. It used for the prevention and treatment of thromboembolic disease including venous thrombosis, thromboembolism, and pulmonary embolism as well as for the prevention of ischemic stroke in patients with atrial fibrillation. Phenprocoumon inhibits vitamin K reductase, resulting in depletion of the reduced form of vitamin K (vitamin KH2). Bleedings are the most important side -effects of oral anticoagulants. The gastrointestinal and the urinary tract are often affected; the most dangerous are intracerebral hemorrhages. A great number of drugs increase the risk of bleeding of oral anticoagulants. Enzyme inhibitors (e.g. allopurinol, androgens, cimetidine, ciprofloxacin, co-trimoxazole, certain anti-inflammatory agents, fibrates, imidazoles, macrolide antibiotics, etc.) reinforce, and enzyme inducers (e.g. barbiturates, rifampicin) and oral contraceptives reduce, the anticoagulant action.   NCATS

Chemistry

  • SMILES: CCC(C1=C(O)c2ccccc2OC1=O)c3ccccc3
  • InChIKey: DQDAYGNAKTZFIW-UHFFFAOYSA-N
  • Mol. Mass: 280.32
  • ALogP: 4.04
  • ChEMBL Molecules:
    phenprocoumon  
    phenprocoumon  
More Chemistry

Pharmacology

Alternative names

3-(1-phenylpropyl)-4-hydroxycoumarin | 3-(1'-phenyl-propyl)-4-oxycoumarin | 3-(alpha-ethylbenzyl)-4-hydroxycoumarin | 3-(alpha-phenylpropyl)-4-hydroxycoumarin | 4-hydroxy-3-(1-phenylpropyl)-2h-1-benzopyran-2-one | 4-hydroxy-3-(1-phenylpropyl)-2h-chromen-2-one | fencumar | fenprocumon | fenprocumone | liquamar | marcoumar | marcumar | phenprocoumarol | phenprocoumarole | phenprocoumon | phenprocoumone | phenprocoumonum | phenprocumone

Organizations (32)

Research & Development (31)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (20)

Approved Indications (4)


 

Brain Infarction (approved 1957)

Pulmonary Embolism (approved 1957)

Thromboembolism (approved 1957)

Venous Thrombosis (approved 1957)

Experimental Indications - Clinical Trial Phases 1-4 (18)


 

Acute Coronary Syndrome (Phase 4)

Anticoagulants (Phase 4)

Atherosclerosis (Phase 4)

Atrial Fibrillation (Phase 4)

Cervix Uteri (Phase 4)

Coronary Disease (Phase 4)

Heart Valve Diseases (Phase 4)

Hemorrhage (Phase 2)

Kidney Failure, Chronic (Phase 3)

Melanoma (Phase 1)

Neoplasms (Phase 3)

Percutaneous Coronary Intervention (Phase 3)

Postoperative Complications (Phase 4)

Pulmonary Embolism (Phase 4)

Thrombosis (Phase 4)

Vascular Calcification (Phase 4)

Venous Thromboembolism (Phase 3)

Venous Thrombosis (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 19
  • # of Trial Organizations: 31

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue